The US Food and Drug Administration last week reiterated its warning that adults treated with antidepressants must be closely observed by their doctors in case they experience worsening of depression and “increased suicidal thinking or behavior.”

Agency officials simultaneously posted new information that a “higher than expected rate of suicide attempts was observed” among patients taking the antidepressant duloxetine (manufactured by Eli Lilly and marketed in the United States as Cymbalta).

Eli Lilly has objected to the FDA's warning about duloxetine. According to a report in the Wall Street Journal (1 July; …